Company news
Neurizon Therapeutics Limited news in 2022
Neurizon Therapeutics Limited's news releases, calls and decks from 2022, newest first.
PharmAust Canine Trial Update clarification
December 20, 2022
PharmAust Canine Trial Update
December 19, 2022
MND Trial Completes Enrolment of First Patient Cohort
December 1, 2022
DNDi contract extension for PharmAust subsidiary Epichem
November 3, 2022
First Patient Dosed in MND Phase 1/2 Trial
October 2, 2022
First Patient in US Canine Cancer Trials Begins Treatment
September 6, 2022
Update on PharmAust Canine Cancer Trials
August 17, 2022
PharmAust Clinical Trials Update
May 23, 2022
PharmAust receives $210k prepayment of forecast R&D rebate
May 17, 2022
MPL tablets arrive in Melbourne for MND Clinical Trial
May 15, 2022
PharmAust Expands Lymphoma Canine Trial to the USA
May 10, 2022
PharmAust Receives $708k R&D Tax Incentive Refund
April 18, 2022
PAA appoints trial manager & receives $200k from FightMND
April 7, 2022
MPL manufactured and tableting commenced
March 14, 2022
Preliminary MPL antiviral leukaemia preclinical WEHI results
February 23, 2022
Key Appointment to Progress MPL COVID-19 Clinical Trial
February 20, 2022
Appendix 4D & Half Year Report
February 18, 2022
Epichem Confirms Effectiveness of OHD E-Waste Project
February 15, 2022
Update on Manufacture of MPL & Tablets for Clinical Trials
February 1, 2022
Decks in 2022
- PharmAust — ANZCVS Annual Scientific Conference "Science Week" 2022
Conference · 6 slides · Jun 24, 2022
- Epichem — Technical Presentation (February 2022)
Technical · 20 slides · Feb 16, 2022